Drugs / Ritivixibat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05642468 | Jan 2023 → Jul 2025 | primary sclerosing cholangitis | Albireo, an Ipsen Company | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ritivixibat | “Drug: Ritivixibat” NCT05642468 ↗ |
| Modality | Small molecule | — CHEMBL5314482 ↗ |
| Route | Oral | “administered orally” NCT05642468 ↗ |